Workflow
设备类产品
icon
Search documents
强瑞技术2025年中报简析:营收净利润同比双双增长,应收账款上升
Zheng Quan Zhi Xing· 2025-08-26 23:09
据证券之星公开数据整理,近期强瑞技术(301128)发布2025年中报。截至本报告期末,公司营业总收 入8.4亿元,同比上升74.64%,归母净利润5490.69万元,同比上升15.57%。按单季度数据看,第二季度 营业总收入5.23亿元,同比上升58.04%,第二季度归母净利润4294.58万元,同比下降0.82%。本报告期 强瑞技术应收账款上升,应收账款同比增幅达51.05%。 本次财报公布的各项数据指标表现一般。其中,毛利率23.21%,同比减32.67%,净利率8.43%,同比减 34.67%,销售费用、管理费用、财务费用总计4864.13万元,三费占营收比5.79%,同比减28.21%,每股 净资产8.01元,同比减27.92%,每股经营性现金流-0.35元,同比减162.93%,每股收益0.53元,同比减 17.45% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 4.81亿 | 8.4亿 | 74.64% | | 归母浄利润(元) | 4750.95万 | 5490.69万 | 15.57% | ...
联影医疗:1Q25业绩重回增长,看好全年发展-20250429
HTSC· 2025-04-29 07:05
Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 158.03 [7][8]. Core Views - The company has returned to growth in Q1 2025, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items showing year-on-year increases of 5.4%, 1.9%, and 26.1% respectively [1]. - The company is expected to achieve steady growth in 2025, driven by improved domestic equipment update policies and ongoing global expansion efforts [1][4]. Summary by Sections Financial Performance - For 2024, the company reported revenue of RMB 103.00 billion, a year-on-year decline of 9.7%, with net profit attributable to the parent at RMB 12.62 billion, down 36.1% [1]. - In Q1 2025, the company achieved revenue of RMB 24.78 billion, with a gross margin of 49.9%, reflecting a 0.4 percentage point increase year-on-year [1]. Business Segments - Equipment Products: Revenue for 2024 was RMB 84.45 billion, down 14.9% year-on-year, but the RT business grew by 18.1% due to superior product performance [2]. - Maintenance Services: Revenue for 2024 was RMB 13.56 billion, up 26.8% year-on-year, with a gross margin of 63.4% [2]. Market Position - Domestic Market: Revenue in 2024 was RMB 80.34 billion, down 17.5% year-on-year, but the company maintained the highest market share in new imaging products in China [3]. - International Market: Revenue in 2024 was RMB 22.66 billion, up 35.1% year-on-year, with operations in over 85 countries [3]. Earnings Forecast and Valuation - The company is projected to have EPS of RMB 2.43, 2.93, and 3.53 for 2025, 2026, and 2027 respectively, with a target price based on a 65x PE ratio for 2025 [4][6].
联影医疗(688271):1Q25业绩重回增长,看好全年发展
HTSC· 2025-04-29 06:40
Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 158.03 [7][8]. Core Views - The company has returned to growth in Q1 2025, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items showing year-on-year increases of 5.4%, 1.9%, and 26.1% respectively [1]. - The company is expected to achieve steady growth in 2025, driven by improved domestic equipment update policies and ongoing global expansion efforts [1]. Revenue and Profitability - For 2024, the company reported revenues of RMB 103.00 billion, a year-on-year decline of 9.7%, with net profit attributable to the parent at RMB 12.62 billion, down 36.1% [1]. - In Q1 2025, the company achieved revenues of RMB 24.78 billion, with a gross margin of 49.9%, reflecting a 0.4 percentage point increase year-on-year [1]. Business Segments - Equipment Products: In 2024, revenue from equipment products was RMB 84.45 billion, down 14.9% year-on-year, but the RT business saw a revenue increase of 18.1% [2]. - Maintenance Services: Revenue from maintenance services in 2024 was RMB 13.56 billion, up 26.8% year-on-year, with a gross margin of 63.4% [2]. Market Performance - Domestic Market: In 2024, domestic revenue was RMB 80.34 billion, down 17.5% year-on-year, but the company maintained the highest market share in new imaging products [3]. - International Market: In 2024, international revenue reached RMB 22.66 billion, up 35.1% year-on-year, with operations in over 85 countries [3]. Earnings Forecast and Valuation - The earnings per share (EPS) forecast for 2025 is RMB 2.43, with a projected PE ratio of 65x for 2025 [4]. - The target price of RMB 158.03 corresponds to a 54x PE for 2025, compared to a comparable company average PE of 45x [4].